HKHiroaki Kitano

Hiroaki Kitano

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hiroaki Kitano has a total of 435 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Discovering and exploring the hidden diversity of human gut viruses using highly enriched virome samples

    by Moreno Zolfo, Andrea Silverj, Aitor Blanco-Miguez, Paolo Manghi, Omar Rota-Stabelli, Vitor Heidrich, Joardan Jensen, Sagun Maharjan, Eric Franzosa, Cristina Menni, et al.

    Viruses are an abundant and crucial component of the human microbiome, but accurately discovering them via metagenomics is still challenging. Currently, the available viral reference genomes poorly represent the diversity in microbiome samples, and expanding such a set of viral references is difficult. As a result, many viruses are still undetectable through metagenomics even when considering the power of de novo metagenomic assembly and binning, as viruses lack universal markers. Here, we describe a novel approach to catalog new viral members of the human gut microbiome and show how the resulting resource improves metagenomic analyses. We retrieved >3,000 viral-like particles (VLP) enriched metagenomic samples (viromes), evaluated the efficiency of the enrichment in each sample to leverage the viromes of highest purity, and applied multiple analysis steps involving assembly and comparison with hundreds of thousands of metagenome-assembled genomes to discover new viral genomes. We reported over 162,000 viral sequences passing quality control from thousands of gut metagenomes and viromes. The great majority of the retrieved viral sequences (∼94.4%) were of unknown origin, most had a CRISPR spacer matching host bacteria, and four of them could be detected in >50% of a set of 18,756 gut metagenomes we surveyed. We included the obtained collection of sequences in a new MetaPhlAn 4.1 release, which can quantify reads within a metagenome matching the known and newly uncovered viral diversity. Additionally, we released the viral database for further virome and metagenomic studies of the human microbiome.


  • Top Cited Papers
    Open Access

    The Evolution, Assembly, and Dynamics of Marine Holobionts

    by Raúl A. González-Pech, Vivian Y. Li, Vanessa Garcia, Elizabeth Boville, Marta Mammone, Hiroaki Kitano, Kim B. Ritchie, Mónica Medina

    The holobiont concept (i.e., multiple living beings in close symbiosis with one another and functioning as a unit) is revolutionizing our understanding of biology, especially in marine systems. The earliest marine holobiont was likely a syntrophic partnership of at least two prokaryotic members. Since then, symbiosis has enabled marine organisms to conquer all ocean habitats through the formation of holobionts with a wide spectrum of complexities. However, most scientific inquiries have focused on isolated organisms and their adaptations to specific environments. In this review, we attempt to illustrate why a holobiont perspective—specifically, the study of how numerous organisms form a discrete ecological unit through symbiosis—will be a more impactful strategy to advance our understanding of the ecology and evolution of marine life. We argue that this approach is instrumental in addressing the threats to marine biodiversity posed by the current global environmental crisis.


  • Stories of QRIO and PINO, and Beyond: Lessons Learned from Small Humanoid Projects From R&D to Business

    by Masahiro Fujita, Yasunori Kawanami, Kiyokazu Miyazawa, Masaya Kinoshita, Kunihito Sawai, Fuminori Yamasaki, Tatsuya Matsui, Ken Endo, Shu Ishiguro, Hiroaki Kitano

    In 1997, Sony announced AIBO, a fully autonomous small quadruped robot for home entertainment, and in 1999 the company began selling it as a consumer product. Soon after development, two small humanoid robots were announced. One was QRIO by Sony, which is about 60[ ]cm height body with dynamical bipedal walking and whole-body cooperative control. The other was PINO by the ERATO Kitano Symbiotic Systems Project, which is about 70[ ]cm height body, Open HW/SW with inexpensive off-the-shelf component. In this paper, we revisit the two humanoids and nearly 20-year-old technologies, and discuss what were done 20 years ago, what have been achieved and what challenges are ahead.


  • Open Access

    Human immune and gut microbial parameters associated with inter-individual variations in COVID-19 mRNA vaccine-induced immunity

    by Masato Hirota, Miho Tamai, Sachie Yukawa, Naoyuki Taira, Melissa M. Matthews, Takeshi Toma, Yu Seto, Makiko Yoshida, Sakura Toguchi, Mio Miyagi, et al.

    COVID-19 mRNA vaccines induce protective adaptive immunity against SARS-CoV-2 in most individuals, but there is wide variation in levels of vaccine-induced antibody and T-cell responses. However, the mechanisms underlying this inter-individual variation remain unclear. Here, using a systems biology approach based on multi-omics analyses of human blood and stool samples, we identified several factors that are associated with COVID-19 vaccine-induced adaptive immune responses. BNT162b2-induced T cell response is positively associated with late monocyte responses and inversely associated with baseline mRNA expression of activation protein 1 (AP-1) transcription factors. Interestingly, the gut microbial fucose/rhamnose degradation pathway is positively correlated with mRNA expression of AP-1, as well as a gene encoding an enzyme producing prostaglandin E2 (PGE2), which promotes AP-1 expression, and inversely correlated with BNT162b2-induced T-cell responses. These results suggest that baseline AP-1 expression, which is affected by commensal microbial activity, is a negative correlate of BNT162b2-induced T-cell responses.


  • Open Access

    A versatile and interoperable computational framework for the analysis and modeling of COVID-19 disease mechanisms

    by Anna Niarakis, Marek Ostaszewski, Alexander Mazein, Inna Kuperstein, Martina Kutmon, Marc E. Gillespie, Akira Funahashi, Marcio Luis Acencio, Ahmed Hemedan, Michael Aichem, et al.

    The COVID-19 Disease Map project is a large-scale community effort uniting 277 scientists from 130 Institutions around the globe. We use high-quality, mechanistic content describing SARS-CoV-2-host interactions and develop interoperable bioinformatic pipelines for novel target identification and drug repurposing. Community-driven and highly interdisciplinary, the project is collaborative and supports community standards, open access, and the FAIR data principles. The coordination of community work allowed for an impressive step forward in building interfaces between Systems Biology tools and platforms. Our framework links key molecules highlighted from broad omics data analysis and computational modeling to dysregulated pathways in a cell-, tissue- or patient-specific manner. We also employ text mining and AI-assisted analysis to identify potential drugs and drug targets and use topological analysis to reveal interesting structural features of the map. The proposed framework is versatile and expandable, offering a significant upgrade in the arsenal used to understand virus-host interactions and other complex pathologies.


  • Open Access

    Social impact and governance of AI and neurotechnologies

    by Kenji Doya, Arisa Ema, Hiroaki Kitano, Masamichi Sakagami, Stuart Russell


  • Open Access

    Erratum To: COVID‐19 Disease Map, a computational knowledge repository of virus‐host interaction mechanisms

    by Marek Ostaszewski, Anna Niarakis, Alexander Mazein, Inna Kuperstein, Robert Phair, Aurelio Orta‐Resendiz, Vidisha Singh, Sara Sadat Aghamiri, Marcio Luis Acencio, Enrico Glaab, et al.

    We need to effectively combine the knowledge from surging literature with complex datasets to propose mechanistic models of SARS‐CoV‐2 infection, improving data interpretation and predicting key targets of intervention. Here, we describe a large‐scale community effort to build an open access, interoperable and computable repository of COVID‐19 molecular mechanisms. The COVID‐19 Disease Map (C19DMap) is a graphical, interactive representation of disease‐relevant molecular mechanisms linking many knowledge sources. Notably, it is a computational resource for graph‐based analyses and disease modelling. To this end, we established a framework of tools, platforms and guidelines necessary for a multifaceted community of biocurators, domain experts, bioinformaticians and computational biologists. The diagrams of the C19DMap, curated from the literature, are integrated with relevant interaction and text mining databases. We demonstrate the application of network analysis and modelling approaches by concrete examples to highlight new testable hypotheses. This framework helps to find signatures of SARS‐CoV‐2 predisposition, treatment response or prioritisation of drug candidates. Such an approach may help deal with new waves of COVID‐19 or similar pandemics in the long‐term perspective.


  • Open Access

    COVID19 Disease Map, a computational knowledge repository of virus–host interaction mechanisms

    by Marek Ostaszewski, Anna Niarakis, Alexander Mazein, Inna Kuperstein, Robert Phair, Aurelio Orta‐Resendiz, Vidisha Singh, Sara Sadat Aghamiri, Marcio Luis Acencio, Enrico Glaab, et al.

    We need to effectively combine the knowledge from surging literature with complex datasets to propose mechanistic models of SARS‐CoV‐2 infection, improving data interpretation and predicting key targets of intervention. Here, we describe a large‐scale community effort to build an open access, interoperable and computable repository of COVID‐19 molecular mechanisms. The COVID‐19 Disease Map (C19DMap) is a graphical, interactive representation of disease‐relevant molecular mechanisms linking many knowledge sources. Notably, it is a computational resource for graph‐based analyses and disease modelling. To this end, we established a framework of tools, platforms and guidelines necessary for a multifaceted community of biocurators, domain experts, bioinformaticians and computational biologists. The diagrams of the C19DMap, curated from the literature, are integrated with relevant interaction and text mining databases. We demonstrate the application of network analysis and modelling approaches by concrete examples to highlight new testable hypotheses. This framework helps to find signatures of SARS‐CoV‐2 predisposition, treatment response or prioritisation of drug candidates. Such an approach may help deal with new waves of COVID‐19 or similar pandemics in the long‐term perspective.


  • Top Cited Papers
    Open Access

    Nobel Turing Challenge: creating the engine for scientific discovery

    by Hiroaki Kitano

    Scientific discovery has long been one of the central driving forces in our civilization. It uncovered the principles of the world we live in, and enabled us to invent new technologies reshaping our society, cure diseases, explore unknown new frontiers, and hopefully lead us to build a sustainable society. Accelerating the speed of scientific discovery is therefore one of the most important endeavors. This requires an in-depth understanding of not only the subject areas but also the nature of scientific discoveries themselves. In other words, the “science of science” needs to be established, and has to be implemented using artificial intelligence (AI) systems to be practically executable. At the same time, what may be implemented by “AI Scientists” may not resemble the scientific process conducted by human scientist. It may be an alternative form of science that will break the limitation of current scientific practice largely hampered by human cognitive limitation and sociological constraints. It could give rise to a human-AI hybrid form of science that shall bring systems biology and other sciences into the next stage. The Nobel Turing Challenge aims to develop a highly autonomous AI system that can perform top-level science, indistinguishable from the quality of that performed by the best human scientists, where some of the discoveries may be worthy of Nobel Prize level recognition and beyond.